Dr Catherine Jacobson, PhD
Director of Clinical Research at Tilray.
Tilray are a Canadian medical cannabis provider licensed by the federal government. At Tilray, Dr. Jacobson is responsible for organizing clinical trials to advance scientific understanding of the therapeutic potential and risks of medicines derived from cannabis. She is currently working with researchers at world-class hospitals and universities on trials involving Tilray’s pharmaceutical-grade medical cannabis products.
Dr. Jacobson obtained a Ph.D. in Neuroscience from the Oregon Health & Science University, and completed post-doctoral fellowships at UCSF and Stanford. In 2013, Dr. Jacobson published the first account of parental treatment of pediatric epilepsy patients with cannabis in the peer-reviewed journal Epilepsy & Behavior. This work led her back to UCSF, where she set up the first compassionate access program for pure CBD (GW’s Epidiolex) for children with severe, treatment-resistant epilepsy. Her work now focuses on tackling some of the largest practical and scientific challenges facing medical cannabis clinical use and research, with the ultimate goal of generating the information physicians need to make informed decisions about patient treatment, as well as the information that policymakers need to make informed, thoughtful decisions on policies that will govern not only access for research purposes, but also access to the patient.